OliX Pharmaceuticals signs agreement with LGC to accelerate production of asymmetric siRNA for the treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration
News - LGC will produce active pharmaceutical ingredients for preclinical and clinical study of OLX301D programme
16 June 2020